down-arrow icon pointed-base

Our Mission

Marvel Medtech’s Solada™ iMR-IGI system represents a paradigm-shifting technology platform that will enable the transformation of MRI from a diagnostic-only imaging modality into a practical and efficient imaging-guided intervention (IGI) and, ultimately, imaging-guided therapy (IGT)–capable clinical resource.  Using MRI for minimally invasive IGI and IGT procedures represents a new revenue stream for healthcare facilities that have made the multi-million dollar investment in whole body MRI scanner systems for diagnostic imaging.  By enabling interactive MRI-guided interventions and therapies, Marvel Medtech’s Solada™ iMR-IGI platform also offers opportunities for breakthroughs in reduction of healthcare costs, in improved outcomes, and in patient comfort and satisfaction.

While the concept of using MRI-compatible robotics for IGI and IGT procedures is broadly applicable to many interventional or therapeutic applications where the superior imaging capabilities of MRI are most beneficial, Marvel Medtech has chosen to focus on initially applying its Solada™ iMR-IGI technology to the intervention and minimally invasive treatment of breast disease.  Marvel Medtech’s iMR-IGI platform technology effectively addresses the impediments to efficient and effective breast interventions using MR imaging guidance.  The Company’s present mission is to reduce healthcare costs and improve the outcomes and satisfaction of breast cancer patients by introducing a market-transforming platform technology that enables interactive MR image-guided intervention, ultimately including minimally invasive image-guided therapies.

We believe our innovative Solada™ iMR-IGI technology will help make the significant advantages of MRI for detecting breast cancer more available and more accessible to many more women who can benefit from these clinically proven significant advantages of MRI.  The Company’s aim is to commercialize the Solada™ iMR-IGI technology for the installed base of clinical MRI scanners first in Europe, followed by North America, then throughout the world.